elevated liver enzymes with tirzepatide Effect of Treatment on Hepatic Biomarkers in Patients Metabolic Dysfunction‐Associated Steatotic Disease and Type 2 Diabetes Mellitus - Arai - 2025 - Hepatology Research A Rare Case of Tirzepatide-Induced

At week 32, time of glucose values in range (70-180 mg/dl) measured by CGM was 88.9 Percentage with CagriSema, 76.2 Percentage with semaglutide and 71.7 Percentage with cagrinlitide [10]

HIP were loaded in SEDDS by incubation of complexes corresponding to 2 mg of semaglutide with SEDDS in a concentration of 50 mg/mL for 30 min in an ultrasonic bath and incubation for 48 h under shaking conditions (1200 rpm, RT)

These drugs are made following current good manufacturing practice

Most patients experience: Mild swelling or tenderness Temporary firmness or redness Minimal downtime (return to daily activities the same day) Results develop gradually over several weeks